An interventional study of Topical 2-Deoxy-D-ribose Hydrogel and Topical Minoxidil 5% Solution in Androgenic Alopecia, sponsored by Kasr El Aini Hospital. Recruiting at 1 site in Egypt. Open to participants aged 18 Years to 50 Years. Per ClinicalTrials.gov, last updated 2026-04-06.
Sponsored by Kasr El Aini Hospital · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 25 studies in Alopecia with a site in Egypt — 9 open to participants now, 9 under way, 1 of them phase 3. Alopecia · Egypt.
Among the 25 studies in Alopecia with a site in Egypt, this one is the 3rd largest by planned enrollment of the 21 interventional ones that give a count, is one of 5 that started in 2026, is one of 12 with no phase, and was the 20th registered.
512 studies on the registry are indexed under Alopecia; 129 are open to participants now.
Browse Alopecia studies →9 of the 25 studies in Alopecia with a site in Egypt are open now. Recruiting first, the newest first:
Kasr El Aini Hospital · Sites in Egypt
Ages 18–50 · Men only · Healthy volunteers
Sohag University · Sites in Egypt
Ages 15–60 · Women only · Healthy volunteers
Sherief Ayman Hussein Shaamash · Sites in Egypt
Ages 18–40 · Men only
Cairo University · Sites in Egypt
Ages 12–50 · Healthy volunteers
Assiut University · Sites in Egypt
Ages 18–50
A study can be open while its sites in Egypt have not opened yet or have stopped. Only those recruiting at a site in Egypt →
Of the 75 Alopecia studies recruiting now, 25 (33%) set no upper age limit and 46 (61%) stop at 75 or younger; 9 take children under 18; 24 take healthy volunteers.
This study: 18 Years to 50 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
25 studies; the count open now beside each. This study's row is marked.
First in 2012; this study’s year is marked. 5 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 60 is above the median of 50 across 431 interventional studies indexed under Alopecia.
Median enrollment 40 across the 21 interventional studies, 63 across the 4 observational. Of the 11 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
None of the 25 has an industry lead sponsor. The 10 most frequent:
Kasr El Aini Hospital is the lead sponsor of 287 studies on the registry; 34 are open to participants now.
Kasr El Aini Hospital has 5 studies filed under Alopecia — fewer than ten, so there is no comparison to draw.
None of the studies under way reaches primary completion within a year.
Among the 25 studies in Alopecia with a site in Egypt, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Androgenetic alopecia is a common form of hair loss that can affect quality of life. This randomized controlled trial aims to evaluate the efficacy and safety of topical 2-Deoxy-D-ribose (2dDR) hydrogel compared with topical minoxidil 5% solution in the treatment of mild to moderate androgenetic alopecia in adults aged 18 to 50 years. Sixty participants will be randomized into 2 treatment groups. The 2dDR group will apply 1 gram of topical 2dDR hydrogel once daily to the affected scalp areas for 6 months. The minoxidil group will apply topical minoxidil 5% solution to the affected scalp areas for 6 months according to sex-specific dosing in the protocol.
Participants will undergo clinical assessment, trichoscopic evaluation, and standardized scalp photography at baseline, Week 12, and Week 24. The study will also assess tissue vascular endothelial growth factor (VEGF) levels using scalp biopsy specimens obtained at baseline and after 3 months of treatment in both groups. Safety will be evaluated through adverse event monitoring and clinical scalp examination during follow-up visits.
Androgenetic alopecia (AGA) is a common androgen-dependent, genetically determined form of hair loss characterized by progressive shortening of the anagen phase, prolongation of telogen, and miniaturization of hair follicles. It commonly affects the frontal scalp, mid-scalp, and vertex in males, and typically presents as diffuse thinning over the crown with preservation of the frontal hairline in females. In addition to hormonal and genetic factors, inflammatory and oxidative stress-related mechanisms have been implicated in the pathogenesis of AGA.
Minoxidil is one of the currently approved treatments for AGA and is thought to improve hair growth through effects on scalp microcirculation, vascular endothelial growth factor (VEGF) expression, and direct stimulation of hair follicles. Recent preclinical studies have suggested that 2-Deoxy-D-ribose (2dDR), a deoxypentose sugar with pro-angiogenic properties, may stimulate angiogenesis through upregulation of VEGF and may promote hair regrowth. Based on these findings, this study is designed to compare topical 2dDR hydrogel with topical minoxidil 5% solution in patients with AGA and to investigate a possible mechanism of action through tissue VEGF assessment.
This study is a randomized controlled trial that will include 60 adult participants aged 18 to 50 years with mild to moderate AGA. Eligible male participants will have Hamilton-Norwood grades II to V, and eligible female participants will have Ludwig grades I to II. Participants will be recruited from the dermatology outpatient clinic of Cairo University Hospital. After informed consent and screening, eligible participants will be randomized into 1 of 2 treatment groups.
Participants in the 2dDR group will apply 1 gram (2 fingertip units) of topical 2dDR hydrogel once daily to targeted scalp areas for 6 months. Participants in the minoxidil group will apply topical minoxidil 5% solution to targeted scalp areas for 6 months, using 1 cc twice daily for men and once daily for women, as specified in the protocol.
Clinical evaluations will include medical history, family history, assessment of disease severity, trichoscopy, and standardized global scalp photography. Trichoscopic assessments will include hair density, terminal hair density, vellus hair density, average hair thickness, follicular unit density, percentage of hairs per follicular unit, and average follicular hairs per unit in predefined scalp areas. Standardized photographs will be obtained at baseline, Week 12, and Week 24 and assessed by blinded dermatologists using a 7-point global photographic scale. Participants will also complete patient global assessment and patient satisfaction evaluation at Week 12 and Week 24.
For biochemical assessment, scalp biopsy specimens will be obtained at baseline and after 3 months of treatment in both study groups to measure tissue VEGF levels by ELISA. In the 2dDR group, an additional biopsy will be obtained from a subset of participants after 3 months for histopathological evaluation of vascular proliferation, follicular thickness, and follicle count.
The primary outcome measures are the changes in terminal hair density and total hair density after 12 weeks of treatment, as well as the change in tissue VEGF levels from baseline to Week 12. Secondary outcomes include changes in terminal and total hair density at Week 24, physician-rated global photographic assessment, patient global assessment, patient satisfaction, safety based on adverse events and scalp examination, and correlation of treatment response with clinical and demographic variables.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants assigned to this arm will apply 1 gram (2 fingertip units) of topical 2-Deoxy-D-ribose hydrogel once daily to the targeted scalp areas for 6 months.
Drug: Topical 2-Deoxy-D-ribose Hydrogel
Participants assigned to this arm will apply topical minoxidil 5% solution to the targeted scalp areas for 6 months. Male participants will apply 1 cc twice daily, and female participants will apply 1 cc once daily.
Drug: Topical Minoxidil 5% Solution
Topical 2-Deoxy-D-ribose hydrogel prepared with sodium alginate. The hydrogel will be composed of sodium alginate, propylene glycol, 2-phenoxyethanol, and 2-Deoxy-D-ribose in water. Participants will apply 1 gram once daily to targeted scalp areas for 6 months.
Topical minoxidil 5% solution administered to targeted scalp areas for 6 months. Male participants will apply 1 cc twice daily, and female participants will apply 1 cc once daily.
Change in Terminal Hair Density
Change in terminal hair density in the predefined trichoscopic assessment areas after 12 weeks of treatment, compared between the topical 2-Deoxy-D-ribose hydrogel group and the topical minoxidil 5% solution group.
Time frame: Baseline to Week 12
Change in Total Hair Density
Change in total hair density in the predefined trichoscopic assessment areas after 12 weeks of treatment, compared between the topical 2-Deoxy-D-ribose hydrogel group and the topical minoxidil 5% solution group.
Time frame: Baseline to Week 12
Change in Tissue VEGF Level
Change in tissue vascular endothelial growth factor (VEGF) levels from baseline to Week 12, measured using scalp biopsy specimens in both treatment groups.
Time frame: Baseline to Week 12
Change in Terminal Hair Density at Week 24
Change in terminal hair density in the predefined trichoscopic assessment areas after 24 weeks of treatment, compared between the topical 2-Deoxy-D-ribose hydrogel group and the topical minoxidil 5% solution group.
Time frame: Baseline to Week 24
Change in Total Hair Density at Week 24
Change in total hair density in the predefined trichoscopic assessment areas after 24 weeks of treatment, compared between the topical 2-Deoxy-D-ribose hydrogel group and the topical minoxidil 5% solution group.
Time frame: Baseline to Week 24
Global Photographic Assessment
Change in standardized scalp photographs assessed independently by 3 blinded dermatologists using a 7-point modified physician global assessment scale ranging from -3 (significant disease progression) to 3 (excellent improvement).
Time frame: Week 12 and Week 24
Patient Global Assessment
Participant-reported overall improvement using a 5-point scale: 0 = no improvement, 1 = mild response (less than 25%), 2 = moderate response (25% to 49%), 3 = good response (50% to 74%), and 4 = very good response (75% or more).
Time frame: Week 12 and Week 24
Patient Satisfaction Score
Participant-reported treatment satisfaction using a 10-point visual analogue scale ranging from 0 (not satisfied at all) to 10 (completely satisfied).
Time frame: Week 12 and Week 24
Incidence of Treatment-Emergent Adverse Events
Safety assessment of topical 2-Deoxy-D-ribose hydrogel based on adverse events, including erythema, itching, pain, allergic or irritant contact dermatitis, and undesirable hair texture, as evaluated through participant history, diary records, and clinical scalp examination.
Time frame: Baseline to Week 24
Correlation of Treatment Response With Clinical and Demographic Variables
Association between treatment response and selected clinical and demographic variables collected during the study.
Time frame: Baseline to Week 24
Plan to share: No — Individual participant data (IPD) will not be shared because this is a single-center study with a small sample size, and de-identification cannot be fully guaranteed. Aggregate results, including summary statistics and outcome analyses, will be made available through publication
No publications or documents are linked to this record.
Started Jan 2026 (actual). Primary completion is estimated for Oct 2026, 9 months after the start.
Of 85 non-industry interventional studies with no phase under Alopecia, half reached primary completion within 13 months of starting (the median), counting those still running; a quarter within 8 and three quarters within 46. This study's planned 9 months is below that.
Counting every sponsor, half of 146 studies reached it within 12 months; a quarter within 6 and three quarters within 27.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.